It's like **Alnylam Pharmaceuticals** for neurological disorders and hair loss, but using its own unique 'Spherical Nucleic Acid' (SNA) technology.

An early-stage **CRISPR Therapeutics**, but applying its novel nucleic acid platform to neurological diseases and hair loss, with major pharma partnerships.

• SNA Technology: A proprietary spherical nucleic acid technology used as the foundation for developing various therapies.
• SCN9A: A preclinical program candidate focused on developing treatments for neuropathic and chronic pain.
• SNA-based treatments for hair loss disorders: Therapies developed in collaboration with AbbVie Inc. targeting hair loss conditions.
• Novel spherical nucleic acids for Huntington's disease: Research and development of therapies in collaboration with Ipsen S.A. for Huntington's disease.
• Novel spherical nucleic acids for Angelman syndrome: Research and development of therapies in collaboration with Ipsen S.A. for Angelman syndrome.

Exicure (XCUR) sells primarily to other companies through collaboration agreements for the development and commercialization of its proprietary spherical nucleic acid (SNA) technology. Its major customers, based on these agreements, are:

• AbbVie Inc. (Symbol: ABBV)
• Ipsen S.A. (Symbol: IPN)

Key Risks to Exicure, Inc. (XCUR)

1. Going Concern and Inability to Obtain Additional Financing: Exicure's management has repeatedly stated that its existing cash and cash equivalents are insufficient to fund operations, leading to substantial doubt about the company's ability to continue as a going concern. The company requires significant additional financing in the near term to cover expenses and pursue strategic alternatives. There is no assurance that such financing will be available on acceptable terms or at all.

2. Product Development and Regulatory Risk in New Focus Area: Following a significant restructuring and the termination of prior collaborations (with AbbVie and Ipsen), Exicure has pivoted its business model, acquiring GPCR Therapeutics USA Inc. and focusing on developing therapeutics for hematologic diseases, with a lead program (burixafor/GPC-100) for stem cell mobilization. As a biotechnology company, Exicure faces inherent risks associated with drug development, including potential failures in preclinical or clinical trials, and the extensive regulatory hurdles required for product approval. Their previous lead candidate, SCN9A, was suspended after failing to meet desired target engagement levels in later preclinical studies, illustrating the high-risk nature of drug development.

3. Nasdaq Delisting Risk: Exicure has received multiple deficiency notices from Nasdaq regarding its listing requirements, including compliance with the minimum bid price rule. Failure to meet these requirements could result in the delisting of its common stock, which would negatively impact the stock's liquidity and the company's ability to access capital markets.

Exicure, Inc., a biotechnology company focusing on therapies for neurological disorders and hair loss, operates in several significant addressable markets globally.

Neuropathic and Chronic Pain

For neuropathic pain, one of Exicure's stated areas of focus, the global market size was valued at approximately USD 8.15 billion in 2025 and is projected to reach USD 15.37 billion by 2033, demonstrating a Compound Annual Growth Rate (CAGR) of 8.29% during the forecast period of 2026-2033. In the United States alone, the neuropathic pain market was valued at USD 2.95 billion in 2025 and is expected to grow to USD 5.47 billion by 2033.

The broader chronic pain market, which encompasses neuropathic pain, was estimated at USD 77.30 billion globally in 2025 and is anticipated to grow to USD 125.84 billion by 2032, with a CAGR of 7.2% from 2025 to 2032. North America held the largest market share for chronic pain treatment, accounting for over USD 40 billion in 2024.

Huntington's Disease

The global market for Huntington's disease treatment was valued at approximately USD 1.39 billion in 2025 and is projected to reach USD 4.33 billion by 2034, exhibiting a CAGR of 13.9% during the forecast period. North America held the largest revenue share in the Huntington's disease treatment market in 2024. Specifically, the United States accounted for the largest market size for Huntington's disease, representing more than 70% of the total in the seven major markets (7MM: US, EU4, UK, and Japan). The U.S. market alone is expected to hold USD 1.22 billion in 2025.

Angelman Syndrome

The market for Angelman syndrome across the seven major markets (US, EU4, UK, and Japan) was valued at USD 109.5 million in 2024 and is expected to reach USD 175.8 million by 2035, growing at a CAGR of 4.41% from 2025 to 2035. The United States holds the largest patient pool and represents the largest market for Angelman syndrome treatment.

Hair Loss Disorders

The global hair loss treatment market was estimated to be valued at USD 4.78 billion in 2025 and is expected to reach USD 7.28 billion in 2032, with a CAGR of 6.2% from 2025 to 2032. Another report indicates the global alopecia market size was USD 25.27 billion in 2025 and is projected to grow to USD 49.30 billion by 2034, at a CAGR of 7.75% during the forecast period of 2026-2034. North America is estimated to hold a dominant position in the global hair loss treatment market, with approximately 33.5% of the market share in 2025. The U.S. alopecia market size was valued at USD 3.59 billion in 2025. More specifically, the global alopecia areata market size was calculated at USD 3.32 billion in 2024 and is expected to be worth USD 6.92 billion by 2034, expanding at a CAGR of 7.6%.

Exicure (NASDAQ: XCUR) has undergone a significant strategic pivot, shifting its primary focus from its proprietary spherical nucleic acid (SNA) technology and related neurological/hair loss programs to the development of therapeutics for hematologic diseases through the acquisition of GPCR Therapeutics USA Inc. in January 2025. Consequently, the expected drivers of future revenue growth over the next 2-3 years are centered on this new direction and strategic collaborations, rather than its historical pipeline which saw its R&D activities suspended in September 2022.

The key drivers of future revenue growth for Exicure (XCUR) are expected to include:

1. Advancement and Potential Commercialization of Burixafor (GPC-100) in Multiple Myeloma: Exicure's lead program, burixafor (GPC-100), has shown positive results from its Phase 2 trial in multiple myeloma patients, leading to increased investor interest. The company anticipates a full data publication from the ongoing Phase 2 trial in 2026 and is preparing for a potential Phase 3 trial. Successful progression through clinical trials and potential regulatory milestones for burixafor could attract significant partnership or licensing agreements, providing substantial revenue through upfront payments, milestones, and future royalties.
2. Expansion of Burixafor (GPC-100) into New Hematologic Indications: Beyond multiple myeloma, Exicure is planning to expand the burixafor program into additional hematologic diseases, specifically sickle cell disease and acute myeloid leukemia. Successful development and clinical validation in these new indications would significantly broaden the market opportunity for burixafor, potentially leading to additional licensing deals or increased value from existing partnerships, driving future revenue growth.
3. New Strategic Collaborations and Licensing Agreements: As a clinical-stage biotechnology company, Exicure's revenue is currently negligible and relies heavily on capital raises and potential future milestone payments from collaborations. The company is actively exploring strategic alternatives to maximize shareholder value, which includes seeking new strategic partnerships or combinations of various funding approaches. Securing new collaborations related to the burixafor program or other acquired assets, involving upfront payments, research and development funding, and milestone payments, would be a critical driver of revenue growth in the near term.

Capital Allocation Decisions for Exicure (XCUR) Over the Last 3-5 Years

Share Issuance

• Exicure completed a registered direct offering in December 2021, issuing shares worth $11.5 million.
• In September 2022, Exicure announced a private placement financing of $5.4 million through the sale of 3,400,000 shares of common stock to CBI USA, Inc., subject to stockholder approval.
• The company undertook two reverse stock splits: a 1-for-30 reverse stock split on June 29, 2022, and a 1-for-5 reverse stock split effective August 27, 2024, both aimed at regaining compliance with Nasdaq's listing requirements.

Inbound Investments

• In July 2021, Exicure received a $20 million upfront payment from Ipsen as part of an exclusive collaboration that could have yielded up to $1 billion in additional payments for developing therapies for Huntington's disease and Angelman syndrome; however, this agreement was mutually terminated in December 2022.
• An earlier collaboration with AbbVie, initiated in 2019, provided a $25 million upfront payment for hair-loss disorder treatments, with a potential total value of up to $750 million, but this agreement was also mutually terminated in December 2022.
• Exicure secured approximately $14-15 million in capital investments through various share issuances in late 2024, including $10 million from HiTron Systems Inc. and an additional $2 million from institutional investors, with plans for a further $2.4 million.

Outbound Investments

• Exicure signed an MOU in December 2024 to acquire GPCR USA, a subsidiary of GPCR Therapeutics, and for technology transfer and collaborative research. This acquisition was completed on January 19, 2025.
• As part of its License and Collaboration Agreement with GPCR Therapeutics, Exicure made a $1 million milestone payment in January 2026, following the completion of a Phase 2 clinical trial for its stem cell mobilizer, burixafor.

Capital Expenditures

• Capital expenditures for Exicure were -$214,000 in the last 12 months (prior to late 2024).
• Free cash flow of -$8.43 million showed weak coverage of capital expenditures of $172,000.
• Funds secured in late 2024, totaling around $14-15 million, were primarily designated for the acquisition of GPCR USA, clinical trial costs, and ongoing operations.